Daniel J Weiss1, Richard Casaburi2, Robin Flannery3, Michelle LeRoux-Williams3, Donald P Tashkin4. 1. Vermont Lung Center, University of Vermont College of Medicine, Burlington, VT. Electronic address: dweiss@uvm.edu. 2. Los Angeles Biomedical Research Institute, Harbor-University of California, Los Angeles (UCLA) Medical Center, Torrance, CA. 3. Osiris Therapeutics Inc, Columbia, MD. 4. David Geffen School of Medicine, UCLA, Los Angeles, CA.
Abstract
BACKGROUND:COPD is a devastating disease affecting millions worldwide. As disease pathogenesis includes both chronic pulmonary and systemic inflammation, antiinflammatory effects of systemically administered mesenchymal stem cells (MSCs) may decrease inflammation, resulting in improved lung function and quality of life. The goal of this study was to assess safety and to perform an initial evaluation of the potential efficacy of systemic MSC administration to patients with moderate to severe COPD. METHODS:Sixty-two patients at six sites were randomized to double-blinded IV infusions of either allogeneic MSCs (Prochymal; Osiris Therapeutics Inc) or vehicle control. Patients received four monthly infusions (100 × 10⁶ cells/infusion) and were subsequently followed for 2 years after the first infusion. End points included comprehensive safety evaluation, pulmonary function testing (PFT), and quality-of-life indicators including questionnaires, 6MWT, and assessments of systemic inflammation. RESULTS: All study patients completed the full infusion protocol, and 74% completed the 2-year follow-up. There were no infusional toxicities and no deaths or serious adverse events deemed related to MSC administration. There were no significant differences in the overall number of adverse events, frequency of COPD exacerbations, or worsening of disease in patients treated with MSCs. There were no significant differences in PFTs or quality-of-life indicators; however, an early, significant decrease in levels of circulating C-reactive protein (CRP) was observed in patients treated with MSCs who had elevated CRP levels at study entry. CONCLUSIONS:Systemic MSC administration appears to be safe in patients with moderate to severe COPD and provides a basis for subsequent cell therapy investigations. TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT00683722; URL: www.clinicaltrials.gov.
RCT Entities:
BACKGROUND: COPD is a devastating disease affecting millions worldwide. As disease pathogenesis includes both chronic pulmonary and systemic inflammation, antiinflammatory effects of systemically administered mesenchymal stem cells (MSCs) may decrease inflammation, resulting in improved lung function and quality of life. The goal of this study was to assess safety and to perform an initial evaluation of the potential efficacy of systemic MSC administration to patients with moderate to severe COPD. METHODS: Sixty-two patients at six sites were randomized to double-blinded IV infusions of either allogeneic MSCs (Prochymal; Osiris Therapeutics Inc) or vehicle control. Patients received four monthly infusions (100 × 10⁶ cells/infusion) and were subsequently followed for 2 years after the first infusion. End points included comprehensive safety evaluation, pulmonary function testing (PFT), and quality-of-life indicators including questionnaires, 6MWT, and assessments of systemic inflammation. RESULTS: All study patients completed the full infusion protocol, and 74% completed the 2-year follow-up. There were no infusional toxicities and no deaths or serious adverse events deemed related to MSC administration. There were no significant differences in the overall number of adverse events, frequency of COPD exacerbations, or worsening of disease in patients treated with MSCs. There were no significant differences in PFTs or quality-of-life indicators; however, an early, significant decrease in levels of circulating C-reactive protein (CRP) was observed in patients treated with MSCs who had elevated CRP levels at study entry. CONCLUSIONS: Systemic MSC administration appears to be safe in patients with moderate to severe COPD and provides a basis for subsequent cell therapy investigations. TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT00683722; URL: www.clinicaltrials.gov.
Authors: Krisztian Nemeth; Andrea Keane-Myers; Jared M Brown; Dean D Metcalfe; James D Gorham; Jared D Gorham; Virgilio G Bundoc; Victor G Bundoc; Marcus G Hodges; Ivett Jelinek; Satish Madala; Sarolta Karpati; Eva Mezey Journal: Proc Natl Acad Sci U S A Date: 2010-03-15 Impact factor: 11.205
Authors: Meagan Goodwin; Viranuj Sueblinvong; Philip Eisenhauer; Nicholas P Ziats; Laurie LeClair; Matthew E Poynter; Chad Steele; Mercedes Rincon; Daniel J Weiss Journal: Stem Cells Date: 2011-07 Impact factor: 6.277
Authors: Joshua M Hare; Jay H Traverse; Timothy D Henry; Nabil Dib; Robert K Strumpf; Steven P Schulman; Gary Gerstenblith; Anthony N DeMaria; Ali E Denktas; Roger S Gammon; James B Hermiller; Mark A Reisman; Gary L Schaer; Warren Sherman Journal: J Am Coll Cardiol Date: 2009-12-08 Impact factor: 24.094
Authors: Bartolome R Celli; Nicholas Locantore; Julie Yates; Ruth Tal-Singer; Bruce E Miller; Per Bakke; Peter Calverley; Harvey Coxson; Courtney Crim; Lisa D Edwards; David A Lomas; Annelyse Duvoix; William MacNee; Stephen Rennard; Edwin Silverman; Jørgen Vestbo; Emiel Wouters; Alvar Agustí Journal: Am J Respir Crit Care Med Date: 2012-03-15 Impact factor: 21.405
Authors: J Stolk; W Broekman; T Mauad; J J Zwaginga; H Roelofs; W E Fibbe; J Oostendorp; I Bajema; M I M Versteegh; C Taube; P S Hiemstra Journal: QJM Date: 2016-01-27
Authors: Michael A Matthay; Piero Anversa; Jahar Bhattacharya; Bruce K Burnett; Harold A Chapman; Joshua M Hare; Derek J Hei; Andrew M Hoffman; Stella Kourembanas; David H McKenna; Luis A Ortiz; Harald C Ott; William Tente; Bernard Thébaud; Bruce C Trapnell; Daniel J Weiss; Jason X-J Yuan; Carol J Blaisdell Journal: Am J Respir Crit Care Med Date: 2013-08-01 Impact factor: 21.405
Authors: Daniel J Weiss; Jason H T Bates; Thomas Gilbert; W Conrad Liles; Carolyn Lutzko; Jay Rajagopal; Darwin Prockop Journal: Ann Am Thorac Soc Date: 2013-10
Authors: S Keisin Wang; Linden A Green; Natalie A Drucker; Raghu L Motaganahalli; Andres Fajardo; Michael P Murphy Journal: J Vasc Surg Date: 2018-02-01 Impact factor: 4.268
Authors: Melissa J Lathrop; Elice M Brooks; Nick R Bonenfant; Dino Sokocevic; Zachary D Borg; Meagan Goodwin; Roberto Loi; Fernanda Cruz; Chad W Dunaway; Chad Steele; Daniel J Weiss Journal: Stem Cells Transl Med Date: 2014-01-16 Impact factor: 6.940
Authors: Oscar E Simonson; Dimitrios Mougiakakos; Nina Heldring; Giulio Bassi; Henrik J Johansson; Magnus Dalén; Regina Jitschin; Sergey Rodin; Matthias Corbascio; Samir El Andaloussi; Oscar P B Wiklander; Joel Z Nordin; Johan Skog; Charlotte Romain; Tina Koestler; Laila Hellgren-Johansson; Petter Schiller; Per-Olof Joachimsson; Hans Hägglund; Mattias Mattsson; Janne Lehtiö; Omid R Faridani; Rickard Sandberg; Olle Korsgren; Mauro Krampera; Daniel J Weiss; Karl-Henrik Grinnemo; Katarina Le Blanc Journal: Stem Cells Transl Med Date: 2015-08-18 Impact factor: 6.940